跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 380 条关于
“Waldenström's Macroglobulinemia”
全部
380
临床试验
332
药物
1
机构
0
资讯
47
5年前
FDA Approves Zanubrutinib for Waldenström's Macroglobulinemia Treatment
8个月前
Cellectar Biosciences Advances Iopofosine I 131 Toward European Approval for Waldenström's Macroglobulinemia
去年
BeOne Medicines Receives EMA PRIME Designation for BTK Degrader BGB-16673 in Waldenström's Macroglobulinemia
9个月前
Dana-Farber Presents Breakthrough Findings in Blood Cancer Treatment at ASH 2025
去年
Breakthrough Developments in Waldenström Macroglobulinemia Treatment: BTK Inhibitors and Novel Therapies Show Promise
10个月前
Aurigene's MALT1 Inhibitor AUR112 Shows 63.6% Response Rate in Phase 1 Lymphoma Trial
8个月前
ImmunityBio's CD19 CAR-NK Therapy Achieves 15-Month Complete Response in Waldenström Lymphoma
去年
Neoantigen Vaccine Shows Promise in Early-Stage Lymphoplasmacytic Lymphoma
8个月前
Ascentage Pharma Receives FDA Clearance for Novel BTK Protein Degrader APG-3288 in B-Cell Malignancies
去年
FDA Approves New Tablet Formulation of BRUKINSA for All Indications, Reducing Pill Burden for B-Cell Cancer Patients
第 1 页，共 5 页
上一页
下一页
